What interviewers actually evaluate

3M leadership interviews test whether candidates understand how leading a diversified industrial technology company during structural transformation differs from leadership at a stable, single-business enterprise – where CEO Mike Roman (who has led 3M since 2018) has overseen the most significant portfolio transformation in 3M's modern history including the April 2024 Solventum healthcare spinoff that separated a 25%-of-revenue healthcare business and fundamentally changed 3M's identity as a purely industrial technology company, where the PFAS mass tort and Combat Arms earplug litigation created leadership challenges that required balancing transparency with stakeholders against active legal defense, managing workforce morale during sustained reputational pressure, and sustaining innovation investment while allocating capital to multi-billion-dollar settlement obligations, where 3M's historically celebrated innovation culture – including the 15% time program allowing R&D employees to direct a portion of their work toward self-selected projects, the Stage-Gate development process, and the 30% new product revenue vitality metric – faces the challenge of being preserved and reinvigorated through the disruption of a major spinoff and significant organizational restructuring, and where the post-Solventum 3M requires leaders who can define a compelling identity for a three-segment industrial company that retains 3M's technology reputation without the healthcare segment that many stakeholders associated with the company's premium positioning. Leadership at 3M spans portfolio strategy and business transformation (where defining what the post-Solventum 3M stands for, which markets and technologies merit investment, and how to communicate a coherent strategic identity to employees, customers, and investors requires CEO-level clarity about what kind of company 3M is becoming), litigation management and stakeholder trust maintenance (where leading through the PFAS and Combat Arms liability resolution while maintaining employee engagement, customer confidence, and investor trust requires transparent communication that acknowledges the company's responsibilities without undermining its legal position), innovation culture preservation during restructuring (where restructuring decisions including workforce reductions and segment reorganizations create employee uncertainty that, if mismanaged, erodes the psychological safety and creative experimentation that 3M's innovation model depends on), and cross-segment technology platform leadership (where 3M's competitive advantage derives from applying a shared library of 15 core technology platforms – adhesives, abrasives, advanced materials, nonwovens, and others – across diverse end markets, and leadership decisions about where to invest in platform capabilities determine which future product innovations become possible).

Start your free 3M Leadership practice session.

What interviewers actually evaluate

Post-Spinoff Strategic Identity, Innovation Culture Stewardship, and Litigation-Era Leadership

3M leadership interviews probe whether candidates understand how leading through major corporate transformation differs from leading a stable business in the strategic identity redefinition challenge (3M after Solventum is a different company than 3M before – the healthcare business provided defensive growth and margin that will no longer offset industrial cyclicality, and leaders who can define a clear investment thesis for the new 3M, communicate it compellingly to the full range of stakeholders, and make resource allocation decisions consistent with the stated strategy will rebuild stakeholder confidence faster than those who rely on 3M's historical reputation without articulating what the company is now), the innovation culture resilience requirement (3M's innovation model depends on employee confidence that creative risk-taking is valued and protected even when projects fail – restructuring and litigation create organizational anxiety that can suppress the experimental culture that drives 3M's new product vitality metric, and leaders who explicitly reinforce innovation behaviors during periods of disruption will preserve the pipeline that drives long-term competitive position), and the litigation leadership communication discipline (the PFAS and Combat Arms litigation created a multi-year leadership challenge of communicating honestly with employees, customers, communities, and investors about the company's legal obligations and remediation commitments without creating statements that undermine active legal defense – leaders who understand how to acknowledge impacts and responsibilities without converting communications into admissions of liability demonstrate the business-legal judgment that complex corporate litigation demands).

The workforce transformation dimension requires understanding that 3M has undergone significant workforce restructuring alongside the Solventum spinoff – approximately 20,000 employees transferred to Solventum, and the remaining 3M organization has been rightsized for its post-spinoff scale – and that leaders who successfully retained key talent through the transition, maintained engagement among employees uncertain about their future with either company, and built the culture of the new, smaller 3M demonstrate workforce leadership skills that are specific to carve-out and spinoff environments.

What gets scored in every session

Specific, sentence-level feedback.

Dimension	What it measures	How to answer
Post-Solventum strategic vision and identity articulation	Do you understand how to develop and communicate a coherent strategic identity for 3M as a focused industrial technology company after the Solventum spinoff – how to articulate what the three remaining segments (Safety and Industrial, Transportation and Electronics, Consumer) share as a competitive foundation, what the 15 technology platforms provide as cross-segment differentiation, and how to frame the post-Solventum investment thesis for employees, customers, and investors in a way that is compelling without over-promising? We flag leadership answers that describe 3M strategy as diversified innovation without engaging with the specific post-Solventum portfolio decisions that define what the company now is and what it has chosen not to be.	Post-Solventum segment portfolio rationale for shared technology platform leverage, investment thesis articulation for industrial technology company identity, stakeholder communication framing that is honest about transformation without creating uncertainty about strategic direction
Innovation culture leadership during restructuring	Can you describe how to sustain 3M's innovation culture – specifically the 15% time program, Stage-Gate product development investment, and new product vitality metrics – when organizational restructuring, workforce reductions, and litigation pressures create employee uncertainty that can suppress creative risk-taking? We score whether your innovation culture approach engages with the specific behavioral and psychological conditions that 3M's innovation model requires and how leaders can actively reinforce those conditions during disruptive periods rather than assuming the culture will persist on its own.	15% time and Stage-Gate investment protection during restructuring, psychological safety maintenance for creative experimentation during uncertainty, innovation vitality metric communication to signal leadership commitment
PFAS and litigation leadership communication	Do you understand how to lead organizational communication about 3M's PFAS and Combat Arms legal obligations – how to acknowledge the impact on affected communities and veterans in a way that demonstrates genuine accountability, what the internal leadership communication looks like for keeping employees engaged and proud of working at 3M despite the reputational pressure, and how to respond to the tension between transparency and legal defense strategy when employees and customers want more candor than litigation counsel advises? We detect leadership answers that describe litigation management as a legal function without engaging with the organizational leadership dimension of sustaining company morale and stakeholder trust through multi-year liability resolution.	Community and veteran impact acknowledgment without liability admission, employee morale and company pride maintenance during reputational pressure, transparency-versus-legal-strategy tension navigation in leadership communications
Technology platform investment and cross-segment leverage leadership	Can you describe how to make leadership decisions about 3M's 15 core technology platforms – how to prioritize which platform capabilities merit continued R&D investment when resources are constrained, what the governance process looks like for identifying cross-segment opportunities where a new capability in one technology platform creates a product innovation opportunity in multiple business segments simultaneously, and how to lead a business case for platform investment that requires cooperation between segment leaders who each have their own P&L incentives? We flag leadership answers that describe 3M innovation as individual product development without engaging with the platform investment model that generates 3M's cross-market leverage and distinguishes its innovation economics from single-product R&D.	Technology platform investment prioritization under resource constraints, cross-segment opportunity identification for shared platform leverage, P&L-incentive conflict management for platform investment business cases

How a session works

Step 1: Choose a 3M leadership scenario – post-Solventum strategic vision and identity articulation, innovation culture leadership during restructuring, PFAS and litigation leadership communication, or technology platform investment and cross-segment leverage leadership.

Step 2: The AI interviewer asks realistic 3M leadership questions: how you would communicate to 3M's 40,000+ remaining employees what the company stands for and why they should be proud to work at 3M in the immediate aftermath of a major spinoff that transferred 20,000 colleagues to a new company and removed 25% of revenue from the portfolio; how you would respond as a senior 3M leader when a journalist asks you directly whether 3M feels responsible for the PFAS contamination in community water supplies, including how you balance genuine accountability with litigation strategy considerations; or how you would lead the decision about whether to continue investing in 3M's ceramics technology platform when it currently supports products in only one segment but potentially enables a breakthrough in electric vehicle battery components that could be significant in a third segment, given that two segment presidents are skeptical about investing in platform capabilities that don't immediately benefit their P&Ls.

Step 3: You respond as you would in the actual interview. The system scores your answer on strategic identity articulation, innovation culture stewardship, litigation communication leadership, and technology platform investment decision-making.

Step 4: You get sentence-level feedback on what demonstrated genuine 3M transformation leadership expertise and what needs stronger innovation culture preservation specificity or post-Solventum strategic identity clarity.

Frequently Asked Questions

Who is Mike Roman and what has his tenure at 3M involved?
Mike Roman became 3M's CEO in July 2018, succeeding Inge Thulin. His tenure has been defined by three major challenges: the PFAS environmental contamination and litigation that required multi-billion-dollar settlement commitments, the Combat Arms earplug mass tort litigation involving over 230,000 veterans, and the strategic decision to separate 3M's healthcare business as an independent public company. The Solventum spinoff completed in April 2024 was the defining portfolio transformation of Roman's tenure, creating a separate publicly traded healthcare company while repositioning 3M as a focused industrial technology company. Roman has also overseen significant workforce restructuring to rightsize the post-Solventum 3M organization, including announcements of approximately 8,500 job reductions in early 2023.

What is the Solventum spinoff and why did 3M execute it?
The Solventum spinoff separated 3M's Health Care segment into a publicly traded independent company called Solventum in April 2024. The strategic rationale was that 3M's industrial and consumer businesses and its healthcare business were operating with different competitive dynamics, customer relationships, and capital requirements – and that both could pursue their strategies more effectively as independent companies. The separation created a pure-play healthcare company (Solventum) focused on medical solutions, oral care, health information systems, and purification, while 3M became a focused industrial technology company organized around Safety and Industrial, Transportation and Electronics, and Consumer segments. The spinoff was 3M's largest portfolio transaction in decades and required approximately 18 months of preparation.

What is 3M's 15% time program and why is it strategically important?
3M's 15% time program, which predates similar programs at other technology companies, allows employees in technical and R&D roles to spend up to 15% of their working time on self-directed projects outside their primary job responsibilities. Several of 3M's most successful products – including Post-it Notes (invented by Arthur Fry using a repositionable adhesive developed by Spencer Silver) – originated from 15% time experimentation. The program signals that 3M values curiosity and creative experimentation beyond assigned projects, and contributes to the psychological safety that enables the risk-taking required for innovation. Leadership decisions about whether to protect 15% time during periods of resource constraint send significant signals about the organization's genuine commitment to innovation culture.

How does 3M's technology platform model create competitive advantage?
3M organizes its research capabilities around 15 core technology platforms including adhesives, abrasives, nonwovens, advanced materials, ceramics, electronics, and others. Rather than developing product-specific research capabilities, 3M maintains and advances platform capabilities that can be applied across multiple markets and product categories. A new adhesive technology developed for industrial assembly applications might simultaneously enable a medical device adhesive, a consumer mounting product, and a vehicle structural bonding solution. This platform model allows 3M to spread R&D investment across more end markets than a single-product developer of equivalent size, and creates the cross-market innovation leverage that generates the 30% new product vitality metric (the percentage of revenue from products introduced within the past five years) that 3M has tracked as a strategic performance indicator.

How has the PFAS litigation affected 3M's leadership culture and reputation?
The PFAS litigation created a multi-year reputational and leadership challenge for 3M. PFAS chemicals – manufactured by 3M for decades and used in Scotchgard, firefighting foam, and industrial applications – have been found in groundwater and drinking water systems near manufacturing sites and more broadly. The litigation required 3M leadership to navigate the tension between acknowledging the environmental impact of PFAS contamination (which affected communities, veterans exposed to firefighting foam, and wildlife) and maintaining appropriate legal positions in active litigation. The $10.3 billion PFAS water system settlement announced in 2023 and 3M's commitment to cease PFAS manufacturing by 2025 represented major steps toward resolution. Leaders who joined 3M during this period have had to manage employee morale, customer relationships, and community trust during sustained public scrutiny of the company's environmental record.